Acadia Pharmaceuticals Inc (ACAD) stock
ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3027% below fair value
$17.83−0.49 (-2.67%)
Close on Nov 18, 2026Market cap $3.07BP/E 8.1Yield –
Acadia Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Acadia Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $1.14B, up 11.8% year over year. For fiscal 2025 it was $1.07B, up 11.9% from the year before. Over ten years it grew 165.7% a year on average. The highest annual figure on record is $1.07B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.07B | +11.9% |
| FY2024 | Dec 31, 2024 | $957.80M | +31.8% |
| FY2023 | Dec 31, 2023 | $726.44M | +40.4% |
| FY2022 | Dec 31, 2022 | $517.24M | +6.8% |
| FY2021 | Dec 31, 2021 | $484.15M | +9.6% |
| FY2020 | Dec 31, 2020 | $441.76M | +30.3% |
| FY2019 | Dec 31, 2019 | $339.08M | +51.5% |
| FY2018 | Dec 31, 2018 | $223.81M | +79.2% |
| FY2017 | Dec 31, 2017 | $124.90M | +620.7% |
| FY2016 | Dec 31, 2016 | $17.33M | +28311.5% |
| FY2015 | Dec 31, 2015 | $61.00K | -49.2% |
| FY2014 | Dec 31, 2014 | $120.00K | -89.5% |
| FY2013 | Dec 31, 2013 | $1.15M | -76.7% |
| FY2012 | Dec 31, 2012 | $4.91M | +137.4% |
| FY2011 | Dec 31, 2011 | $2.07M | -95.1% |
| FY2010 | Dec 31, 2010 | $42.14M | +558.5% |
| FY2009 | Dec 31, 2009 | $6.40M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $307.96M | +16.4% |
| Q1 FY2026 | Mar 31, 2026 | $268.06M | +9.7% |
| Q4 FY2025 | Dec 31, 2025 | $283.99M | +9.4% |
| Q3 FY2025 | Sep 30, 2025 | $278.63M | +11.3% |
| Q2 FY2025 | Jun 30, 2025 | $264.57M | +9.3% |
| Q1 FY2025 | Mar 31, 2025 | $244.32M | +18.7% |
| Q4 FY2024 | Dec 31, 2024 | $259.60M | +12.4% |
| Q3 FY2024 | Sep 30, 2024 | $250.40M | +18.3% |
| Q2 FY2024 | Jun 30, 2024 | $241.96M | +46.4% |
| Q1 FY2024 | Mar 31, 2024 | $205.83M | +73.8% |
| Q4 FY2023 | Dec 31, 2023 | $231.04M | +69.3% |
| Q3 FY2023 | Sep 30, 2023 | $211.70M | +62.0% |
| Q2 FY2023 | Jun 30, 2023 | $165.24M | +22.8% |
| Q1 FY2023 | Mar 31, 2023 | $118.46M | +2.6% |
| Q4 FY2022 | Dec 31, 2022 | $136.49M | +4.4% |
| Q3 FY2022 | Sep 30, 2022 | $130.71M | -0.7% |
| Q2 FY2022 | Jun 30, 2022 | $134.56M | +16.8% |
| Q1 FY2022 | Mar 31, 2022 | $115.47M | +8.4% |
| Q4 FY2021 | Dec 31, 2021 | $130.76M | +8.1% |
| Q3 FY2021 | Sep 30, 2021 | $131.61M | +9.2% |
| Q2 FY2021 | Jun 30, 2021 | $115.22M | +4.6% |
| Q1 FY2021 | Mar 31, 2021 | $106.55M | +18.3% |
| Q4 FY2020 | Dec 31, 2020 | $121.01M | +23.1% |
| Q3 FY2020 | Sep 30, 2020 | $120.58M | +27.5% |
| Q2 FY2020 | Jun 30, 2020 | $110.10M | +32.3% |
| Q1 FY2020 | Mar 31, 2020 | $90.07M | +43.1% |
| Q4 FY2019 | Dec 31, 2019 | $98.33M | +65.1% |
| Q3 FY2019 | Sep 30, 2019 | $94.59M | +62.2% |
| Q2 FY2019 | Jun 30, 2019 | $83.21M | +45.8% |
| Q1 FY2019 | Mar 31, 2019 | $62.96M | +28.8% |
| Q4 FY2018 | Dec 31, 2018 | $59.57M | +36.7% |
| Q3 FY2018 | Sep 30, 2018 | $58.31M | +63.9% |
| Q2 FY2018 | Jun 30, 2018 | $57.06M | +87.2% |
| Q1 FY2018 | Mar 31, 2018 | $48.87M | +219.7% |
| Q4 FY2017 | Dec 31, 2017 | $43.56M | +264.2% |
| Q3 FY2017 | Sep 30, 2017 | $35.58M | +575.4% |
| Q2 FY2017 | Jun 30, 2017 | $30.48M | – |
| Q1 FY2017 | Mar 31, 2017 | $15.29M | – |
| Q4 FY2016 | Dec 31, 2016 | $11.96M | – |
| Q3 FY2016 | Sep 30, 2016 | $5.27M | – |
See a number that looks wrong?